Breast cancer: monitoring response to neoadjuvant chemotherapy using Tc-99m sestamibi scintimammography

Onkologie. 2003 Feb;26(1):27-31. doi: 10.1159/000069860.


Background: Aim of the study was to assess the value of scintimammography using Tc-99m sestamibi in the evaluation of tumor response to neoadjuvant chemotherapy. MATERIAL ANS METHODS: Results were calculated for 9 patients undergoing neoadjuvant chemotherapy. Scintimammography using 740 MBq Tc-99m sestamibi was performed before, during and after chemotherapy, and sestamibi uptake was scored visually and semiquantitatively to evaluate tumor response.

Results: In the case of complete response (n = 3) sestamibi uptake decreased 8 days after beginning neoadjuvant chemotherapy and normalized in the following course. Focal uptake decreased more slowly in patients with partial response (n = 3), who showed clear, persisting tracer accumulation after therapy. The patients without response (n = 3) showed a persisting high tumor activity even after chemotherapy was completed.

Conclusions: The preliminary data suggest that in contrast to other imaging modalities scintimammography appears to yield early information regarding tumor response to neoadjuvant chemotherapy.

Publication types

  • Evaluation Study

MeSH terms

  • Breast / diagnostic imaging
  • Breast Neoplasms / diagnostic imaging*
  • Breast Neoplasms / drug therapy*
  • Carcinoma, Ductal, Breast / diagnostic imaging*
  • Carcinoma, Ductal, Breast / drug therapy*
  • Epirubicin / administration & dosage
  • Female
  • Follow-Up Studies
  • Humans
  • Magnetic Resonance Imaging
  • Mammography*
  • Neoadjuvant Therapy*
  • Paclitaxel / administration & dosage
  • Predictive Value of Tests
  • Radionuclide Imaging
  • Technetium Tc 99m Sestamibi*
  • Treatment Outcome


  • Epirubicin
  • Technetium Tc 99m Sestamibi
  • Paclitaxel